NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
“Strategic LOI with BioXtek could fast‑track U.S. exosome manufacturing and de‑risk clinical rollout”
NurExone’s U.S. subsidiary Exo‑Top signed a non‑binding Letter of Intent (LOI) with Florida‑based BioXtek to explore a strategic partnership covering GMP manufacturing, clinical supply, and commercialization of naïve MSC‑derived exosomes. The collaboration would combine Exo‑Top’s Master Cell Bank and exosome expertise with BioXtek’s U.S. GMP facilities and distribution network, targeting wound care, pain management, orthopedics and regenerative aesthetics (a market projected > $1.6 B by 2034). It also envisions BioXtek producing exosomes for NurExone’s lead candidate ExoPTEN (acute spinal cord injury & optic nerve damage) while retaining rights for internal therapeutic programs.
Key points: - No cash consideration at signing; partnership remains subject to due‑diligence, board/TSXV approvals and regulatory clearances. - Potential to secure a reliable U.S. manufacturing source and open commercial revenue streams beyond the core pipeline. - Aligns with earlier sublicensing (Mar 2026) and BioFab accelerator acceptance (Nov 2025) that aimed to build U.S. GMP capacity.
The LOI represents a material positive development:
- De‑risking of manufacturing: Prior updates highlighted the need for U.S. scale‑up (BioFab Lab, Indianapolis incentive). This LOI directly addresses that gap by tying Exo‑Top’s proprietary MCB to an established GMP partner.
- Catalyst for clinical timelines: Securing a domestic supply chain could accelerate IND filing and trial material availability for ExoPTEN, which has orphan drug designation.
- Revenue upside: Beyond internal use, the agreement opens a commercial channel for naïve MSC exosomes in high‑growth wound‑care and aesthetics markets—potentially diversifying revenue streams.
- Financial impact: No immediate cash inflow, but the partnership may reduce future capital outlays for building U.S. facilities, preserving runway (cash per share ≈ $0.0127 as of Sep 2025).
Compared with historical trajectory: - Early 2025 pre‑clinical data and financing rounds built a pipeline but left manufacturing uncertain. - Mid‑2025 sublicensing and BioFab acceptance were incremental steps; the LOI is the first concrete external manufacturing commitment, moving from “plan” to “partner”.
Thus, while not yet a binding contract, the announcement materially improves the company’s execution outlook and is likely to be priced positively by the market.
NurExone Biologic Inc. (TSXV: NRX) develops exosome‑based regenerative medicines. Flagship candidate ExoPTEN is a naïve MSC‑derived exosome loaded with PTEN‑siRNA targeting acute spinal cord injury and optic nerve damage, holding orphan drug designation in the U.S. The platform also supports naïve exosomes for wound care, pain management, orthopedics and aesthetics.